aTyr Pharma, Inc.

ATYR

NASDAQ

Healthcare

Biotechnology

San Diego, CA, US56 employeesatyrpharma.com

$0.85

-0.00(-0.31%)

Mkt Cap $83M

$0.65

$6.61

52-Week Range

At a Glance

AI-generated

aTyr Pharma, Inc.

Revenue breakdown: Collaboration Revenue (100%).

8-K

aTyr Pharma announced fourth quarter and full year 2025 results, reporting a net loss of $74.1 million for the year ended December 31, 2025. The company ended 2025 with $80.9 million in cash and investments and scheduled a Type C meeting with the FDA for mid-April 2026 to review the Phase 3 EFZO-FIT study results.

$83M

Market Cap

$190.1K

Revenue

-$74M

Net Income

Employees56

Fundamentals

How The Business Makes Money

Revenue by Segment

Collaboration Revenue100%($800.0K)

Activity

What Changed Recently

Financial Results

Mar 4, 2026

, including Exhibit 99.1 hereto is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as

Peer Companies

Company	Price	Change	Market Cap	P/E
RLMDRelmada Therapeutics, Inc...	$7.00	-1.41%	$513M	-7.0
UNCYUnicycive Therapeutics, I...	$6.96	-2.32%	$149M	-3.7
RPTXRPTX	$2.65	+0.00%	$114M	—
ALXOALX Oncology Holdings Inc...	$1.99	+0.25%	$108M	-1.2
CAMPCAMP4 Therapeutics Corpor...	$4.45	-0.34%	$94M	-3.0
DTILPrecision BioSciences, In...	$5.83	+2.46%	$75M	-1.8
HYFTMindWalk Holdings Corp.	$1.16	+1.75%	$54M	-6.3
MGXMetagenomi, Inc. Common S...	$1.35	+0.75%	$51M	-0.6

Analyst View

Company Profile

CIK0001339970

ISINUS0021202025

CUSIP002120202

Phone858 731 8389

Address10240 Sorrento Valley Road, San Diego, CA, 92121, US

SEC EDGAR